Clinical-stage antibody company Generate:Biomedicines is the latest biotech to mull going public as momentum for IPOs continues to build. The Flagship-founded biotech has yet to set out how many ...

Generate Biomedicines, Inc. (GENB) has filed to raise public capital in an IPO to advance its pipeline of treatment candidates, according to an SEC filing. The company is developing treatments for ...

Passkeys provide stronger security than traditional passwords and could eventually replace them entirely as adoption grows. We explain everything you need to know and show you how to get started. I ...

ThreatsDay Bulletin tracks active exploits, phishing waves, AI risks, major flaws, and cybercrime crackdowns shaping this ...

I pushed eight free AI chatbots to their limits to find the best AI chatbots of 2026. To explore our top picks, check out ZDNET's chatbot-by-chatbot guide.

David Reid does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond their ...

Dan Peguine, a tech entrepreneur and marketing consultant based in Lisbon, lets a precocious, lobster-themed AI assistant called Moltbot run much of his life. Peguine, a self-professed early adopter ...